| Title |
Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B
|
|---|---|
| Published in |
PharmacoEconomics, December 2012
|
| DOI | 10.1007/s40273-012-0009-2 |
| Pubmed ID | |
| Authors |
María Buti, Itziar Oyagüez, Virginia Lozano, Miguel A. Casado |
| Abstract |
Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Student > Ph. D. Student | 5 | 13% |
| Other | 4 | 11% |
| Student > Master | 4 | 11% |
| Student > Bachelor | 3 | 8% |
| Other | 7 | 18% |
| Unknown | 6 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 42% |
| Agricultural and Biological Sciences | 3 | 8% |
| Economics, Econometrics and Finance | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Business, Management and Accounting | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 9 | 24% |